Sykes Lab

The principal objective of my laboratory is to identify and define those molecular features that drive leukemogenesis and then use that information to develop rational therapeutic strategies for improving outcomes in acute leukemia.

The lab is most interested in molecular pathways that: 1) are differentially regulated between malignant cells and their healthy counterparts; 2) promote resistance to conventional chemotherapies; and 3) support leukemia stem cell biology. Based on these criteria, lab projects fall within one or more of the following three themes:

1. Intracellular Metabolism: Due to the distinct metabolic dependencies of many human cancers, cellular metabolism has emerged as both a major point of investigation and therapeutic targeting in cancer biology. Based our recently published studies, we are currently investigating the following metabolic processes in acute leukemia: Amino acid and nucleotide metabolism, cellular energetics and polyunsaturated fatty acid metabolism.
2. Unfolded Protein Response: The unfolded protein response or UPR is a signal transduction network that helps cells negotiate multiple cellular stresses such as endoplasmic reticulum (ER) stress, metabolic stress, responses to chemotherapy and more. We and others have shown that certain sub-types of acute leukemia are highly dependent upon UPR signaling. To extend these findings, we are currently focused on determining the upstream and downstream UPR components that support acute leukemia as well as assessing the therapeutic efficacy of targeting these pathways in leukemia.
3. Regulation of Mitochondrial Biology: Mitochondria represent the engines of the cell and are often commandeered for the purpose of maximal energy output in many forms of human cancer, including acute leukemia. While these organelles are often strictly thought of as energy generators, mitochondria are increasingly being recognized as multi-faceted systems that require an ensemble of regulators to maintain proper function. Our aim is to elucidate these regulators and in particular those that are hijacked in human cancer.

Importantly, because leukemia arises from mutated hematopoietic stem and progenitor cells (HSPCs) I am also very interested in assessing how these pathways influence healthy HSPC biology.

Principal investigator

Stephen Sykes, PhD

Associate Professor of Pediatrics, Hematology & Oncology

• Phone: 314-454-6018

Recent publications

• Disruption of polyunsaturated fatty acid biosynthesis drives STING-dependent acute myeloid leukemia cell maturation and death
  May 1, 2024
  Disruption of polyunsaturated fatty acid biosynthesis drives STING-dependent acute myeloid leukemia cell maturation and deathKanefsky, J., Basse, M., Sokei, J., di Martino, O., Valin, L., Jaspers, Y., Martinez, E., Huhn, J., Di Marcantonio, D., Magee, J. A., Goldman, A. R., Tang, H. Y., Ferraro, F., Kemp, S., Wiest, D. L. & Sykes, S. M., May 2024, In: Journal of Biological Chemistry. 300, 5, 107214.Research output: Contribution to journal › Article › peer-review
• Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasms
  February 10, 2024
  Multiomic profiling reveals metabolic alterations mediating aberrant platelet activity and inflammation in myeloproliferative neoplasmsHe, F., Laranjeira, A. B. A., Kong, T., Lin, S., Ashworth, K. J., Liu, A., Lasky, N. M., Fisher, D. A. C., Cox, M. J., Fulbright, M. C., Antunes-Heck, L., Yu, L. Y., Brakhane, M., Gao, B., Sykes, S. M., D’Alessandro, A., Paola, J. D. & Oh, S. T., Feb 10 2024, In: Journal of Clinical Investigation. 134, 3, e172256.Research output: Contribution to journal › Article › peer-review
• DNA polymerase θ protects leukemia cells from metabolically induced DNA damage
  May 11, 2023
  DNA polymerase θ protects leukemia cells from metabolically induced DNA damageVekariya, U., Toma, M., Nieborowska-Skorska, M., Le, B. V., Caron, M. C., Kukuyan, A. M., Sullivan-Reed, K., Podszywalow-Bartnicka, P., Chitrala, K. N., Atkins, J., Drzewiecka, M., Feng, W., Chan, J., Chatla, S., Golovine, K., Jelinek, J., Sliwinski, T., Ghosh, J., Matlawska-Wasowska, K. & Chandramouly, G. & 18 others, Nejati, R., Wasik, M., Sykes, S. M., Piwocka, K., Hadzijusufovic, E., Valent, P., Pomerantz, R. T., Morton, G., Childers, W., Zhao, H., Paietta, E. M., Levine, R. L., Tallman, M. S., Fernandez, H. F., Litzow, M. R., Gupta, G. P., Masson, J. […]
• The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasm
  July 28, 2022
  The ERK2-DBP domain opposes pathogenesis of a mouse JAK2V617F-driven myeloproliferative neoplasmZhang, Y., Truong, B., Fahl, S. P., Martinez, E., Cai, K. Q., Al-Saleem, E. D., Gong, Y., Liebermann, D. A., Soboloff, J., Dunbrack, R., Levine, R. L., Fletcher, S., Kappes, D., Sykes, S. M., Shapiro, P. & Wiest, D. L., Jul 28 2022, In: Blood. 140, 4, p. 359-373 15 p.Research output: Contribution to journal › Article › peer-review
• TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitors
  October 1, 2021
  TET2 and DNMT3A mutations exert divergent effects on DNA repair and sensitivity of leukemia cells to PARP inhibitorsMaifrede, S., Le, B. V., Nieborowska-Skorska, M., Golovine, K., Sullivan-Reed, K., Dunuwille, W. M. B., Nacson, J., Hulse, M., Keith, K., Madzo, J., Caruso, L. B., Gazze, Z., Lian, Z., Padella, A., Chitrala, K. N., Bartholdy, B. A., Matlawska-Wasowska, K., Marcantonio, D. D., Simonetti, G. & Greiner, G. & 15 others, Sykes, S. M., Valent, P., Paietta, E. M., Tallman, M. S., Fernandez, H. F., Litzow, M. R., Minden, M. D., Huang, J., Martinelli, G., Vassiliou, G. S., Tempera, I., Piwocka, K., Johnson, […]